SGLT2 or when metformin is not enough

Česká verzia

Authors: Nesvadba M. ^1,2; Ch. Cmorej P. ^3,4; M; Vostrý ⁴
Authors place of work: Ordinace praktického lékaře, Turnov ¹; Vysoká škola zdravotníctva a sociálnej práce v Bratislave, SR ²; Zdravotnická záchranná služba Ústeckého kraje, p. o. ³; FZS UJEP v Ústí nad Labem ⁴
Published in the journal: Kardiol Rev Int Med 2019, 21(4): 223-224

Summary

The casuistry describes the case of a 53-year-old patient diagnosed with Type 2 diabetes who just started therapy with the inhibitor SGLT2 – dapagliflozin because of unsatisfactory compensation of diabetes treated with metformin to date. After 3 months of treatment, there was an improvement of diabetes compensation and a slight drop in weight.

Keywords:

Prognosis – dapagliflozin – compensation of diabetes

Zdroje

1. Sano M. Hemodynamic effects of sodium-glucose cotransporter 2 inhibitors. J Clin Med Res 2017; 9(6): 457–460. doi: 10.14740/ jocmr3011w.

2. Matthews VB, Elliot RH, Rudnicka C et al. Role of the symphathetic nervous systém in regulation of the sodium glucose cotransporter 2. J Hypertens 2017; 35(10): 2059–2068. doi: 10.1097/ HJH.0000000000001434.

3. Mayer GJ, Wanner C, Weir MR et al. Analysis from the EMPA-REG OUTCOME trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics. Kidney Int 2019; 96(2): 489–504. doi: 10.1016/ j.kint.2019.02.033.

4. Kvapil M. Dapagliflozin: klinické aspekty použití. Farmakoterapie 2014; 10(1): 83–87.

5. Haluzík M a kol. Praktická léčba diabetu. 2. vyd. Praha: Mlada fronta 2013.

6. Kvapil M. Glifloziny: Inhibitory SGLT 2. In: Kvapil M. (ed.) Diabetologie 2013. Praha: Triton 2013.

7. Nauck MA, Del Prato S, Meier JJ et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized,52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011; 34(9): 2015–2022. doi: 10.2337/ dc11-0606.

8. Kvapil M. Diabetologie 2014. Praha: Triton 2014.

9. Wanner C, Lachin JM, Inzucchi SE et al. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus established cardiovascular disease, and chronic kidney disease. Circulation 2018; 137(2): 119–129. doi: 10.1161/ CIRCULATIONAHA.117.028268.